Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice
Adiponectin is an antidiabetic and antiatherogenic adipokine, which plays distinct roles in the balance of energy homoeostasis. As an insulin sensitizing hormone, adiponectin exerts multiple biological effects by the specific receptors (AdipoR1 and AdipoR2), through activation of AMP-activated prote...
Gespeichert in:
Veröffentlicht in: | European journal of pharmaceutical sciences 2016-10, Vol.93, p.123-131 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 131 |
---|---|
container_issue | |
container_start_page | 123 |
container_title | European journal of pharmaceutical sciences |
container_volume | 93 |
creator | Wang, Ying Wan, Yumeng Ye, Guihong Wang, Pu Xue, Xiaowen Wu, Guanzhong Ye, Boping |
description | Adiponectin is an antidiabetic and antiatherogenic adipokine, which plays distinct roles in the balance of energy homoeostasis. As an insulin sensitizing hormone, adiponectin exerts multiple biological effects by the specific receptors (AdipoR1 and AdipoR2), through activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α pathways. AdipoRon, an orally active synthetic small-molecule AdipoR agonist, shows very similar effects to adiponectin in vitro and in vivo, which could be a promising therapeutic approach for obesity-related disorders. In view of the regulatory effects of adiponectin or AdipoRon on inflammatory response and energy metabolism, they might be endowed a curative potential for tissue damage. Hence, its effects and possible mechanism were investigated. In vitro studies on hepatocytes (L02) and macrophages (RAW264.7) suggested a protective and anti-inflammatory potential of AdipoRon. The effects were verified in acute hepatic injury mice induced by d-galactosamine (D-GalN): hepatic lesions were restored by AdipoRon or bicyclol (positive reference drug) pretreatment, which were characterized by a significant increase in serological and hepatic biomarkers (AST, ALT, MDA and NOSs). Besides, AdipoRon attenuated the inflammation in the liver, characterized by the dwindling proinflammatory macrophage infiltration, as well as the shrinkage of tumor necrosis factor-α (TNF-α), transforming growth factor beta 1 (TGF-β1), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6); meanwhile conversely promoted AMPK activation by phosphorylation. Combined with liver histopathology, these results demonstrated the hepatoprotective effects of AdipoRon against D-GalN-induced damage, which might be ascribed to the attenuation of inflammation, inhibition of free radical reactions, as well as enhancement of liver energy metabolism.
[Display omitted] |
doi_str_mv | 10.1016/j.ejps.2016.08.017 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1823029232</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0928098716303062</els_id><sourcerecordid>1823029232</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-3be7bd581988e0d34e8c0bcbaaddbe59e13d9641e4fab5d968e9fb830d4a98143</originalsourceid><addsrcrecordid>eNp9kE1LxDAYhIMouq7-AQ_So5fWN2m7TcDLIn7BgiB68BTS5K2ktE1N2gX_vVlWPXqaOcwMzEPIBYWMAl1dtxm2Y8hY9BnwDGh1QBaUVyKFisEhWYBgPAXBqxNyGkILACtewTE5YVVJV7SEBXl_xFFNbvRuQj3ZLSbYNNGFxDXJ2tjRvbghUR_KDmFKTPqhOqUnF1RvB0ztYGaNJuli0Sd2aGf_FSXprcYzctSoLuD5jy7J2_3d6-1junl-eLpdb1JdMDaleY1VbUpOBecIJi-Qa6h1rZQxNZYCaW7EqqBYNKouo-UomprnYAolOC3yJbna78YPnzOGSfY2aOw6NaCbg6Sc5cAEy1mMsn1UexeCx0aO3vbKf0kKcodUtnKHVO6QSuAyIo2ly5_9ue7R_FV-GcbAzT6A8eXWopdBWxwiF-sjSWmc_W__G6NtiYM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1823029232</pqid></control><display><type>article</type><title>Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wang, Ying ; Wan, Yumeng ; Ye, Guihong ; Wang, Pu ; Xue, Xiaowen ; Wu, Guanzhong ; Ye, Boping</creator><creatorcontrib>Wang, Ying ; Wan, Yumeng ; Ye, Guihong ; Wang, Pu ; Xue, Xiaowen ; Wu, Guanzhong ; Ye, Boping</creatorcontrib><description>Adiponectin is an antidiabetic and antiatherogenic adipokine, which plays distinct roles in the balance of energy homoeostasis. As an insulin sensitizing hormone, adiponectin exerts multiple biological effects by the specific receptors (AdipoR1 and AdipoR2), through activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α pathways. AdipoRon, an orally active synthetic small-molecule AdipoR agonist, shows very similar effects to adiponectin in vitro and in vivo, which could be a promising therapeutic approach for obesity-related disorders. In view of the regulatory effects of adiponectin or AdipoRon on inflammatory response and energy metabolism, they might be endowed a curative potential for tissue damage. Hence, its effects and possible mechanism were investigated. In vitro studies on hepatocytes (L02) and macrophages (RAW264.7) suggested a protective and anti-inflammatory potential of AdipoRon. The effects were verified in acute hepatic injury mice induced by d-galactosamine (D-GalN): hepatic lesions were restored by AdipoRon or bicyclol (positive reference drug) pretreatment, which were characterized by a significant increase in serological and hepatic biomarkers (AST, ALT, MDA and NOSs). Besides, AdipoRon attenuated the inflammation in the liver, characterized by the dwindling proinflammatory macrophage infiltration, as well as the shrinkage of tumor necrosis factor-α (TNF-α), transforming growth factor beta 1 (TGF-β1), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6); meanwhile conversely promoted AMPK activation by phosphorylation. Combined with liver histopathology, these results demonstrated the hepatoprotective effects of AdipoRon against D-GalN-induced damage, which might be ascribed to the attenuation of inflammation, inhibition of free radical reactions, as well as enhancement of liver energy metabolism.
[Display omitted]</description><identifier>ISSN: 0928-0987</identifier><identifier>EISSN: 1879-0720</identifier><identifier>DOI: 10.1016/j.ejps.2016.08.017</identifier><identifier>PMID: 27516150</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>AdipoR agonist ; AdipoRon ; Animals ; Cell Line, Transformed ; d-Galactosamine (D-GalN) ; Galactosamine - adverse effects ; Hepatic injury ; Hepatoprotective effects ; Humans ; Inflammation ; Liver - drug effects ; Male ; Mice ; Mice, Inbred C57BL ; Piperidines - pharmacology</subject><ispartof>European journal of pharmaceutical sciences, 2016-10, Vol.93, p.123-131</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-3be7bd581988e0d34e8c0bcbaaddbe59e13d9641e4fab5d968e9fb830d4a98143</citedby><cites>FETCH-LOGICAL-c422t-3be7bd581988e0d34e8c0bcbaaddbe59e13d9641e4fab5d968e9fb830d4a98143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0928098716303062$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27516150$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Wan, Yumeng</creatorcontrib><creatorcontrib>Ye, Guihong</creatorcontrib><creatorcontrib>Wang, Pu</creatorcontrib><creatorcontrib>Xue, Xiaowen</creatorcontrib><creatorcontrib>Wu, Guanzhong</creatorcontrib><creatorcontrib>Ye, Boping</creatorcontrib><title>Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice</title><title>European journal of pharmaceutical sciences</title><addtitle>Eur J Pharm Sci</addtitle><description>Adiponectin is an antidiabetic and antiatherogenic adipokine, which plays distinct roles in the balance of energy homoeostasis. As an insulin sensitizing hormone, adiponectin exerts multiple biological effects by the specific receptors (AdipoR1 and AdipoR2), through activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α pathways. AdipoRon, an orally active synthetic small-molecule AdipoR agonist, shows very similar effects to adiponectin in vitro and in vivo, which could be a promising therapeutic approach for obesity-related disorders. In view of the regulatory effects of adiponectin or AdipoRon on inflammatory response and energy metabolism, they might be endowed a curative potential for tissue damage. Hence, its effects and possible mechanism were investigated. In vitro studies on hepatocytes (L02) and macrophages (RAW264.7) suggested a protective and anti-inflammatory potential of AdipoRon. The effects were verified in acute hepatic injury mice induced by d-galactosamine (D-GalN): hepatic lesions were restored by AdipoRon or bicyclol (positive reference drug) pretreatment, which were characterized by a significant increase in serological and hepatic biomarkers (AST, ALT, MDA and NOSs). Besides, AdipoRon attenuated the inflammation in the liver, characterized by the dwindling proinflammatory macrophage infiltration, as well as the shrinkage of tumor necrosis factor-α (TNF-α), transforming growth factor beta 1 (TGF-β1), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6); meanwhile conversely promoted AMPK activation by phosphorylation. Combined with liver histopathology, these results demonstrated the hepatoprotective effects of AdipoRon against D-GalN-induced damage, which might be ascribed to the attenuation of inflammation, inhibition of free radical reactions, as well as enhancement of liver energy metabolism.
[Display omitted]</description><subject>AdipoR agonist</subject><subject>AdipoRon</subject><subject>Animals</subject><subject>Cell Line, Transformed</subject><subject>d-Galactosamine (D-GalN)</subject><subject>Galactosamine - adverse effects</subject><subject>Hepatic injury</subject><subject>Hepatoprotective effects</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Liver - drug effects</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Piperidines - pharmacology</subject><issn>0928-0987</issn><issn>1879-0720</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LxDAYhIMouq7-AQ_So5fWN2m7TcDLIn7BgiB68BTS5K2ktE1N2gX_vVlWPXqaOcwMzEPIBYWMAl1dtxm2Y8hY9BnwDGh1QBaUVyKFisEhWYBgPAXBqxNyGkILACtewTE5YVVJV7SEBXl_xFFNbvRuQj3ZLSbYNNGFxDXJ2tjRvbghUR_KDmFKTPqhOqUnF1RvB0ztYGaNJuli0Sd2aGf_FSXprcYzctSoLuD5jy7J2_3d6-1junl-eLpdb1JdMDaleY1VbUpOBecIJi-Qa6h1rZQxNZYCaW7EqqBYNKouo-UomprnYAolOC3yJbna78YPnzOGSfY2aOw6NaCbg6Sc5cAEy1mMsn1UexeCx0aO3vbKf0kKcodUtnKHVO6QSuAyIo2ly5_9ue7R_FV-GcbAzT6A8eXWopdBWxwiF-sjSWmc_W__G6NtiYM</recordid><startdate>20161010</startdate><enddate>20161010</enddate><creator>Wang, Ying</creator><creator>Wan, Yumeng</creator><creator>Ye, Guihong</creator><creator>Wang, Pu</creator><creator>Xue, Xiaowen</creator><creator>Wu, Guanzhong</creator><creator>Ye, Boping</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20161010</creationdate><title>Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice</title><author>Wang, Ying ; Wan, Yumeng ; Ye, Guihong ; Wang, Pu ; Xue, Xiaowen ; Wu, Guanzhong ; Ye, Boping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-3be7bd581988e0d34e8c0bcbaaddbe59e13d9641e4fab5d968e9fb830d4a98143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>AdipoR agonist</topic><topic>AdipoRon</topic><topic>Animals</topic><topic>Cell Line, Transformed</topic><topic>d-Galactosamine (D-GalN)</topic><topic>Galactosamine - adverse effects</topic><topic>Hepatic injury</topic><topic>Hepatoprotective effects</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Liver - drug effects</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Piperidines - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ying</creatorcontrib><creatorcontrib>Wan, Yumeng</creatorcontrib><creatorcontrib>Ye, Guihong</creatorcontrib><creatorcontrib>Wang, Pu</creatorcontrib><creatorcontrib>Xue, Xiaowen</creatorcontrib><creatorcontrib>Wu, Guanzhong</creatorcontrib><creatorcontrib>Ye, Boping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ying</au><au>Wan, Yumeng</au><au>Ye, Guihong</au><au>Wang, Pu</au><au>Xue, Xiaowen</au><au>Wu, Guanzhong</au><au>Ye, Boping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice</atitle><jtitle>European journal of pharmaceutical sciences</jtitle><addtitle>Eur J Pharm Sci</addtitle><date>2016-10-10</date><risdate>2016</risdate><volume>93</volume><spage>123</spage><epage>131</epage><pages>123-131</pages><issn>0928-0987</issn><eissn>1879-0720</eissn><abstract>Adiponectin is an antidiabetic and antiatherogenic adipokine, which plays distinct roles in the balance of energy homoeostasis. As an insulin sensitizing hormone, adiponectin exerts multiple biological effects by the specific receptors (AdipoR1 and AdipoR2), through activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor (PPAR)α pathways. AdipoRon, an orally active synthetic small-molecule AdipoR agonist, shows very similar effects to adiponectin in vitro and in vivo, which could be a promising therapeutic approach for obesity-related disorders. In view of the regulatory effects of adiponectin or AdipoRon on inflammatory response and energy metabolism, they might be endowed a curative potential for tissue damage. Hence, its effects and possible mechanism were investigated. In vitro studies on hepatocytes (L02) and macrophages (RAW264.7) suggested a protective and anti-inflammatory potential of AdipoRon. The effects were verified in acute hepatic injury mice induced by d-galactosamine (D-GalN): hepatic lesions were restored by AdipoRon or bicyclol (positive reference drug) pretreatment, which were characterized by a significant increase in serological and hepatic biomarkers (AST, ALT, MDA and NOSs). Besides, AdipoRon attenuated the inflammation in the liver, characterized by the dwindling proinflammatory macrophage infiltration, as well as the shrinkage of tumor necrosis factor-α (TNF-α), transforming growth factor beta 1 (TGF-β1), interleukin-1 beta (IL-1β) and interleukin-6 (IL-6); meanwhile conversely promoted AMPK activation by phosphorylation. Combined with liver histopathology, these results demonstrated the hepatoprotective effects of AdipoRon against D-GalN-induced damage, which might be ascribed to the attenuation of inflammation, inhibition of free radical reactions, as well as enhancement of liver energy metabolism.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27516150</pmid><doi>10.1016/j.ejps.2016.08.017</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0928-0987 |
ispartof | European journal of pharmaceutical sciences, 2016-10, Vol.93, p.123-131 |
issn | 0928-0987 1879-0720 |
language | eng |
recordid | cdi_proquest_miscellaneous_1823029232 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | AdipoR agonist AdipoRon Animals Cell Line, Transformed d-Galactosamine (D-GalN) Galactosamine - adverse effects Hepatic injury Hepatoprotective effects Humans Inflammation Liver - drug effects Male Mice Mice, Inbred C57BL Piperidines - pharmacology |
title | Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T16%3A22%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatoprotective%20effects%20of%20AdipoRon%20against%20d-galactosamine-induced%20liver%20injury%20in%20mice&rft.jtitle=European%20journal%20of%20pharmaceutical%20sciences&rft.au=Wang,%20Ying&rft.date=2016-10-10&rft.volume=93&rft.spage=123&rft.epage=131&rft.pages=123-131&rft.issn=0928-0987&rft.eissn=1879-0720&rft_id=info:doi/10.1016/j.ejps.2016.08.017&rft_dat=%3Cproquest_cross%3E1823029232%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1823029232&rft_id=info:pmid/27516150&rft_els_id=S0928098716303062&rfr_iscdi=true |